Smc horizon scanning anne lee scottish medicines consortium julia earnshaw glaxosmithkline
Download
1 / 18

SMC Horizon Scanning Anne Lee, Scottish Medicines Consortium Julia Earnshaw, GlaxoSmithKline - PowerPoint PPT Presentation


  • 157 Views
  • Uploaded on

SMC Horizon Scanning Anne Lee, Scottish Medicines Consortium Julia Earnshaw, GlaxoSmithKline. SMC Horizon Scanning. Aims and objectives Outputs Process (industry engagement) Key challenges Industry perspective Priorities for development (workshop). Horizon scanning - aims.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' SMC Horizon Scanning Anne Lee, Scottish Medicines Consortium Julia Earnshaw, GlaxoSmithKline' - odele


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Smc horizon scanning anne lee scottish medicines consortium julia earnshaw glaxosmithkline

SMC Horizon ScanningAnne Lee, Scottish Medicines Consortium Julia Earnshaw, GlaxoSmithKline


Smc horizon scanning
SMC Horizon Scanning

  • Aims and objectives

  • Outputs

  • Process (industry engagement)

  • Key challenges

  • Industry perspective

  • Priorities for development (workshop)


Horizon scanning aims
Horizon scanning - aims

To facilitate the managed entry of new medicines and new indications for existing medicines into NHS Scotland

  • early consideration allows advanced financial & service planning by Health Boards

  • should lead to improved patient care through timely access to new treatments



Reporting to date
Reportingto date

  • Forward Look sent to restricted group

    (HB CEO, DoF, lead doctor & pharmacist)

  • Focus on high cost impact medicines

  • Point estimate of uptake and costs at yr 1 and yr 5

    Forward Look 1 Oct 05 & Interim Update Apr 06

    Forward Look 2 Oct 06


Process

Intelligence Gathering

MCNs

RCAGs

SIGs

Clinicians

Other sources

NHS

Process

SMC Forthcoming

Submissions

Pharmaceutical Industry

Public Health

Finance

Prediction

NHS Intelligence /

Pharm Companies

SMC

Cancer HS Steering Gp

Clinical experts

ForwardLook Report


Forward look 2
Forward Look 2

  • Context statement (caveats)

  • Focus on medicines expected to become available 07/08

  • Potential for significant financial impact (+ all orphan medicines)

  • <£500K impact at year 5 – cost impact considered low, generally not included


Forward look 21
Forward Look 2

  • Supplementary Information

    • assumptions / uncertainties

  • Details of medicines considered but not included

  • Update on drugs in Forward Look 1

  • Financial cost templates


Horizon scanning foi
Horizon Scanning – FoI

  • No option of blanket refusal to release data

  • All parties acknowledge information provided on CiC basis

  • All acknowledge FoI legislation

  • SMC is committed to maintaining confidentiality

  • Code of Practice and Confidentiality Agreement circulated with Forward Look 2


Clinical expertise
Clinical expertise

  • SMC clinical expert database

  • Cancer – HS steering group

  • Facilitate links and consultation with specialist groups and networks

  • Review draft HS information / report to ensure fit for purpose

  • What if no consensus?


Industry engagement
Industry engagement

  • Product pipeline intelligence requested 6-monthly

  • Standard documentation developed with UGF

  • Companies alerted to products to be included in report

  • Opportunity to comment on draft information

  • Final copy of information in report


Forward look 2 industry input
Forward Look 2 – industry input

  • Valuable input from 22 of 23 companies

  • Indicative acquisition costs provided for 13 of 22 new medicines / formulations

  • Useful input on estimated uptake

  • Supplementary Information

    • Assumptions and uncertainties


Next steps
Next steps

  • Develop work on total vs direct drug budget impact

    (?which medicines)

  • Support HBs in their use of Forward Look

  • Develop relationship with NHSC / other HS organisations


Challenges
Challenges

? How can companies help

  • Engage all appropriate companies

  • Early identification of products with biggest potential impact

  • Improve net budget impact

    estimates

  • Compare actual vs predicted spend / costs



Why should industry engage
Why should industry engage?

  • Opportunity to communicate with decision makers in line with the C of P

  • Ensure information produced accurate and up to date

    • This will go ahead with or without us!

  • Collaborative working with our ultimate customers

  • Help facilitate market access

    • Budgets more likely to be available

    • Prompt guidance to the service


Issues for industry
Issues for industry

  • Structures within companies – R&D vs LOC

  • Access to accurate information

  • Confidentiality

    • Rationale for R&D staff

  • Lack of certainty

    • Disease area

    • Price

    • Final indication

    • Competitor activities

    • Positioning/uptake

    • Timing of license

  • Resource

  • Review and approval

    • Need for consistent company view

    • Not appropriate to speculate

    • Market sensitivity

  • Timing of information

    • What to do if things change


How issues could be addressed
How issues could be addressed

  • Collaboration on optimising process

  • Predictability/understanding of process

    • What is needed

    • Which products

    • When and with sufficient time to deliver

    • Cleary defined written processes and forms

  • Internal processes

    • Overarching agreed approach

    • Manager with overall responsibility

    • Pre-approved materials

  • Use of ranges/estimates


ad